389650 fundamentals

Nextbiomedical Co. Ltd. engages in the development of therapeutics based on polymer and drug delivery system technologies. It offers the Nexpowder product, which is used for wounds and bleeding sites during hemorrhagic digestive ulcers, endoscopic mucosal resection, and endoscopic submucosal dissection procedures. The company was founded on August 1, 2014 and is headquartered in Incheon, South Korea.